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Abstract
Dysregulation of the cell cycle is the underlying mechanism of neoplasia. Healthy cells prevent
propagation of DNA mutations to progeny by activation of cellular checkpoints, which allows time
for DNA repair. On the other hand, activation of the DNA damage response is also the general
principle of many current cancer treatments. Thus, recent advances in understanding how
checkpoints in the cell cycle work at the molecular level open the door to new approaches to
antitumor therapy.
Introduction
The cell cycle, in which cells replicate their genome and
then physically divide into daughter cells, is an
essential function in keeping multicellular organisms
alive and healthy. However, various environmental
factors (such as ionizing radiation or ultraviolet
irradiation, and chemotherapy) as well as erroneous
physiological processes (such as stalled replication
forks or production of reactive oxygen species from
metabolic reactions) cause undesired mutations that
can lead to genomic instability and cancer. To prevent
transfer of mutations to offspring, cells have evolved
checkpoints that sense DNA damage and prevent
progression through the cell cycle to allow DNA repair.
Checkpoints are controlled by ATM (ataxia telangiec-
tasia mutated) and ATR (ataxia telangiectasia and
Rad3-related protein) kinases that activate their down-
stream effector kinases Chk2 (checkpoint kinase 2) and
Chk1, respectively, and regulate multiple components
of the cell cycle control and DNA repair pathways
[1,2]. If the extent of DNA damage exceeds the capacity
of repair mechanisms, cells are either permanently
withdrawn from the cell cycle (senescence and/or
quiescence) or are eliminated by programmed cell
death (apoptosis). However, in most cases DNA lesions
are successfully repaired and cells re-enter the cell cycle
in a process called checkpoint recovery. Here we discuss
recent advances in our understanding of checkpoint
recovery and its relevance for human cancer.
Recent advances
Proliferating cells repeatedly pass through interphase
(consisting of the G1, S, and G2 phases in which cells
grow, replicate DNA, and duplicate centrosomes, respec-
tively) followed by nuclear division (mitosis) and cellular
division (cytokinesis). Transitions between the phases in
the cell cycle are controlled by evolutionarily conserved
cyclin-dependent kinases (CDKs), which act in complex
with various cyclins, the principal regulators of the cell
cycle. In the case of the G2/M transition, these compo-
nents are represented by Cdk1/cyclin B. Interestingly, data
from mice genetics indicate that Cdk1 is the only essential
CDK, because proliferating cells can substitute for loss
of any other CDK [3]. This indicates that the G2/M
transition is carefully guarded, probably because an arrest
in the G2 checkpoint is the last chance for the cell to
prevent transmission of mutations to progeny. As
untimely activation of Cdk1 can cause premature mitotic
entry with deleterious consequences, activity of Cdk1 is
carefully regulated at multiple levels (see Figure 1) [4].
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G2, just before cells need to activate Cdk1 to promote
mitotic entry. Second, Wee1 and Myt1 kinases directly
inhibit Cdk1 by phosphorylating its Thr-14 and Tyr-15
residues. Removal of these inhibitory modifications is
controlled by members of the CDC25 (cell division cycle
25) family of phosphatases and leads to a rapid activation
of Cdk1/cyclin B. Finally, an initial activation of Cdk1/
cyclin B stimulates the activity of Cdc25 and inactivates
Wee1, creating two feedback loops that result in a switch-
like activation of Cdk1. Activation of the DNA damage
checkpointintheG2phaseleadstoincreasedactivationof
Wee1 as well as to degradation of Cdc25A [5], inhibition
of Cdc25B [6], or cytosolic sequestration of Cdc25C [7,8],
which all contribute to keeping Cdk1 activity low and
preventingmitoticentry.Duringcheckpointrecovery,cells
rely onPlk1 (Polo-like kinase 1),which targets bothWee1
andClaspin(anessentialcofactorofATR)forproteasomal
degradation [9-12]. Plk1 also promotes nuclear transloca-
tion of Cdc25C [13] and directly inhibits Chk2 and the
p53 binding protein 53BP1 [14]. Interestingly, Plk1
activityisredundantin unperturbed mitotic entrywhereas
it becomes essential in checkpoint recovery, and this
function is conserved in organisms ranging from yeast to
humans.ActivityofPlk1islowafterDNAdamagewhereas
it becomes fully active during checkpoint recovery [15].
Phosphorylation within the T-loop of Plk1 is driven by
Aurora-A kinase in complex with an adaptor protein,
hBora, and is essential for activation of Plk1 and for
checkpoint recovery [17]. Apart from its role in recovery,
the yeast Plk1 homolog Cdc5 is indispensable for
adaptation to irreparable DNA damage [17,18]; however,
it remains unclear whether this pathway is conserved also
in higher eukaryotes.
Although Plk1 activity is essential for recovery, it is not
sufficient, indicating that additional control mechanisms
exist. As DNA damage response pathways mostly rely on
phosphorylation of multiple substrates, phosphatases
that counteract such modifications are likely candidates
to be involved in silencing the checkpoint and promot-
ing checkpoint recovery. This was borne out in a study
showing that two members of the protein phosphatase
2C (PP2C) family, Ptc2 and Ptc3, are necessary for
checkpoint recovery in yeast [19]. In mammals, it was
suggested that multiple phosphatases participate in
inhibition of the DNA damage response pathway [20].
Among these, wild-type p53-induced phosphatase 1
(Wip1; also called PP2C-delta or PPM1D) seems to play
a central role because it specifically recognizes a p(S/T)Q
motif, phosphorylated mostly by ATM/ATR kinases,
allowing Wip1 to efficiently dephosphorylate multiple
players in the DNA damage response pathway [21].
Although Wip1 dephosphorylates many targets, the most
relevant for checkpoint recovery is probably the tumor
suppressor p53 [22]. The presence of Wip1 throughout
the checkpoint counteracts the function of p53 as a
transcriptional repressor of mitotic inducers [22] and
thus allows levels of cyclin B and Plk1 to be kept high
enough for eventual checkpoint recovery following
successful repair of damaged DNA [22]. Wip1 can
regulate p53 by multiple mechanisms. Apart from a
direct dephosphorylation of pSer15 on p53, Wip1 has
been shown to decrease p53 levels by activating the
ubiquitin E3 ligase Mdm2, which targets p53 for
proteasomal degradation, and also through activation
of MdmX, which directly inhibits transcriptional activity
of p53 at promoters [23,24]. Determining which one of
these mechanisms is the most physiologically relevant
still remains unaccomplished; however, counteracting
the p53 function seems to be the major role for Wip1.
This view is further supported by finding high expression
levels of Wip1 in tumors that do not have inactivating
mutations in p53 [25]. Conversely, overexpression of
Wip1 is very rare in tumors carrying mutations in p53,
possibly because the selection pressure for amplification
of the Wip1 locus was lost by inactivating p53.
Recent data indicate that driving the G2/M transition is
more complex than previously anticipated. It appears
that apart from mechanisms regulating Cdk1/cyclin B
activity as described above, cells also actively control the
outcome of Cdk1 activation at the level of its multiple
substrates. This is achieved by PP2A-B55d phosphatase,
which actively reverses phosphorylations made by Cdk
during the interphase and thus prevents premature
mitotic entry [26]. Strikingly, the activity of PP2A-B55d
is inhibited by a Greatwall kinase (called MAST-L
[microtubule-associated serine/threonine-protein
kinase-like] in humans) that is active in mitosis and
ensures that cells pass through mitosis with full
phosphorylation of Cdk1 substrates [27-29]. Recently it
h a sb e e nd e m o n s t r a t e dt h a tt h i si sa c h i e v e db y
phosphorylation of a PP2A inhibitor, Arpp19/Ensa
(cAMP-regulated phosphoprotein 19/a-endosulfine),
by Greatwall [30, 31]. Importantly, Greatwall is activated
in mitosis through phosphorylation by Cdk1/cyclin B,
and once phosphorylated, forms a negative feedback
loop to PP2A [32]. In light of these new findings, one can
think of the G2/M transition as a balance between Cdk1/
cyclin B activity and activity of the opposing PP2A
phosphatase. In the normal cell cycle, Cdk1/cyclin B
activity eventually outweighs that of PP2A and cells enter
mitosis. Conversely, checkpoint mechanisms block the
activation of Cdk1 which may push the balance towards
activity of PP2A and prevent mitotic entry. This would
imply that cells that repair DNA lesions and enter mitosis
through a checkpoint recovery pathway need to
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undamaged cells. This suggests that additional mechan-
isms (such as the activity of Plk1) are likely to be
required for checkpoint recovery to support Cdk1 in the
fight against the phosphatase-induced barrier. Moreover,
prolonged arrest in the G2 checkpoint leads to activation
of p53, which causes a drop in levels of cyclin B and Plk1
and further lowers the capacity of cells to recover. It
appears that cells held at the G2 checkpoint adopt
mechanisms (such as activating Wip1 to counteract the
effect of p53) that prevent a drop of mitotic-inducing
activity below a certain threshold and retain competence
for eventual recovery. This model is further supported by
a recent finding that cells need to maintain a basal level
of Cdk activity during a DNA damage-induced G2 arrest
in order to recover [33]. This enables cells to retain the
transcriptional activity of the proliferation-promoting
forkhead box protein FOXM1 throughout the DNA
damage and allows them to sustain high levels of cyclin B
[33]. How the basal activity of Cdk1 is regulated
throughout the DNA damage, however, still remains to
be elucidated. An attractive possibility is that Greatwall
inhibition during the DNA damage response allows
PP2A to reduce the phosphorylation level of some CDK
substrates (leaving the basal Cdk1 activity untouched).
Alternatively, PP2A might only target substrates of some
CDKs, perhaps leaving substrates of Cdk2/cyclin A
(including FOXM1) phosphorylated whereas acting
preferentially on Cdk1 substrates. Clearly more research
needs to be done to fully answer these issues.
Future prospects
Probably the most clinically relevant mode of DNA
damage is represented by the genotoxic stress caused by
radiotherapy or chemotherapy routinely used to cure
cancer. Both strategies rely on induction of a cell death or
permanentcellcyclearrestoftumorcellsexposedtoDNA
damage, but at the same time they are limited by their
toxic effects on normal tissues. With the recent major
advances in understanding the molecular functioning of
cell cycle checkpoints, it is hoped that in the future it may
be possible to pharmacologically target components of
the checkpoint recoverypathway, which mayincrease the
sensitivity of tumor cells to current treatments.
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